ECDC expert opinion on efficacy and effectiveness of neuraminidase inhibitors published for public consultation

Influenza and other Respiratory Viruses

Volumn 10, Issue 3, 2016, Pages 152-153

  Penttinen, Pasi ^a   Catchpole, Mike ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; OSELTAMIVIR; SIALIDASE INHIBITOR; ZANAMIVIR; ANTIVIRUS AGENT; ENZYME INHIBITOR; SIALIDASE;

CONSULTATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; EPIDEMIC; EUROPEAN UNION; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; INFECTION PREVENTION; INFECTION RISK; INFLUENZA; INFLUENZA VIRUS; MEDICAL EXPERT; MORTALITY; NONHUMAN; PANDEMIC INFLUENZA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; PUBLICATION; SEASONAL INFLUENZA; SYMPTOM; ZOONOSIS; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); EXPERT WITNESS; HEALTH CARE POLICY; INFLUENZA, HUMAN; META ANALYSIS (TOPIC); TREATMENT OUTCOME;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; ENZYME INHIBITORS; EUROPEAN UNION; EXPERT TESTIMONY; HEALTH POLICY; HUMANS; INFLUENZA, HUMAN; META-ANALYSIS AS TOPIC; NEURAMINIDASE; TREATMENT OUTCOME; ZANAMIVIR;

EID: 84962034517     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/irv.12377     Document Type: Editorial

References (10)

1. ECDC, Public health use of influenza antivirals during influenza pandemics. ECDC Interim guidance. 2009.
2. Kelly H, Cowling BJ. Influenza: the rational use of oseltamivir. Lancet 2015; 385:1700-1702.
3. Heneghan CJ, Onakpoya I, Thompson M, Spencer EA, Jones M, Jefferson T. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014; 348:g2547.
4. Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014; 348:g2545.
5. Loder E, Tovey D, Godlee F. The Tamiflu trials. BMJ 2014; 348:g2630.
6. Jefferson T, Jones MA, Doshi P Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2014; 4 CD008965.
7. Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet 2015; 385:1729-1737.
8. Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014; 2:395-404.
9. Casscells SW, Granger E, Kress AM, Linton A, Madjid M, Cottrell L. Use of oseltamivir after influenza infection is associated with reduced incidence of recurrent adverse cardiovascular outcomes among military health system beneficiaries with prior cardiovascular diseases. Circ Cardiovasc Qual Outcomes 2009; 2:108-115.
10. Mosby LG, Rasmussen SA, Jamieson DJ. 2009 pandemic influenza A (H1N1) in pregnancy: a systematic review of the literature. Am J Obstet Gynecol 2011; 205:10-18.